Heron Therapeutics Launches Private Infrastructure Investment Strategy for Diversified Investor Access

Heron Therapeutics Expands Offerings with New Infrastructure Investment Strategy

Heron Therapeutics announces the launch of a private infrastructure investing strategy, designed to provide accredited individual investors and family offices with access to a diversified portfolio of over 1,000 infrastructure assets. This strategic initiative aims to connect investors with five seasoned fund managers, each with an impressive average of 20 years of experience in managing private infrastructure funds. The initiative leverages Heron’s proprietary fund scoring process, which could potentially incorporate more fund managers in the future, thereby expanding investment opportunities for its clientele.

The new private infrastructure strategy is particularly notable for its promising early performance, as the underlying private infrastructure funds have yielded an average annualized return of 13.5% after fees since their inception. This performance underscores the attractiveness of private infrastructure as an asset class, especially in the current economic climate where inflation concerns loom large. By broadening its alternatives platform—which already includes private credit and private equity—Heron aims to help investors achieve long-term returns while simultaneously providing a hedge against inflation, a critical consideration for today's investors.

CEO Mike Sall emphasizes that the launch of this strategy significantly enhances the Heron platform, which now features exposure to 20 private market funds selected through a rigorous proprietary ranking process. The assets within this new strategy encompass various sectors, including power generation, transportation, telecommunications, and digital infrastructure, offering varying risk levels and investment categories. The historical resilience of private infrastructure during inflationary periods and market downturns positions it as a compelling investment option, particularly as forecasts suggest that 2026 could be a pivotal year for private infrastructure investments, driven by growth in essential sectors such as power generation and logistics.

In addition to the new infrastructure strategy, Heron Therapeutics continues to focus on providing innovative investment opportunities. The company’s commitment to diversifying investments beyond public markets is timely, as market volatility prompts investors to consider more stable and resilient alternatives. For those seeking further insights into the benefits of investing in private infrastructure, Heron Therapeutics recommends the article titled "Why invest in private infrastructure in 2026? 3 charts for investors," which highlights key data supporting this strategic move.

As Heron Therapeutics deepens its engagement in the private investment landscape, the introduction of the private infrastructure strategy not only enhances its existing portfolio but also reflects a broader trend in the investment community toward diversifying into less correlated asset classes. This strategic expansion is poised to meet the evolving needs of investors seeking stability and growth amidst economic uncertainties.